In the pharmaceutical industry the increased efficiency brought about by new fast chromatography methods needs to be matched by commensurate mass spec capabilities. maXis UHR-TOF is the instrument of choice to keep up with fastest chromatography.
Ray Sanchez, Penggao Duan and Darwin Asa, Bruker Daltonics, Billerica, Massachusetts, USA.
In the pharmaceutical industry the increased efficiency brought about by new fast chromatography methods needs to be matched by commensurate mass spec capabilities. maXis UHR-TOF is the instrument of choice to keep up with fastest chromatography.
Figure 1
Many high performance accurate mass and orbital trapping MS systems are unable to provide sufficient high resolution data at fast chromatography speeds. Fast separation technology can significantly reduce the time required to analyse a given sample. Chromatography methods can be reduced sometimes by an order of magnitude. These short run times produce chromatograms with peak widths of less than a few seconds wide. The new maXis system is the only high performance MS system capable of operating with those fast run times without sacrificing resolution or sensitivity. Here we demonstrate the typical results that can be achieved by the combination of fast chromatography with the maXis to analyse a complex pharmaceutical sample.
Figure 2
UHPLC system:
Mobile phase:
Gradient:
Flow rate: 0.6 mL/min
Injection volume: 2 µL
In this study, the maXis was challenged to identify a series of unknown drug compounds that had been separated by UHPLC. Using a typical reverse phase C18 gradient separation method, 7 of the 10 compounds were base line separated by the UHPLC in 85 seconds at 10 Hz sampling rate. The maXis was then able to discern the presence of 10 compounds in the sample, despite the lack of chromatographic separation of three of the compounds, even at levels as low as 10 pg on column. Furthermore, the excellent mass accuracy (<1 ppm) and resolution (avg ~50 K) of the results generated by the maXis, when used in conjunction with the SmartFormula 3D software, were able to use the data to correctly identify all 10 compounds and unequivically determine their molecular formula. This is exceptional performance from a Q-TOF, especially with a UHPLC speed separation.
MS system: Bruker Daltonics maXis
Spectral acquisition 10 full spectra per second
Dry heater 180 °C
Nebulizer 2 Bar
Capillary 4500 V
Dry gas 6 L/min
ESI positive polarity
Range 100–800 m/z
Calibrant Lithium formate (16 mM)
LockMass calibration methylstearate
Technology
Bruker Daltonics has developed a new state of the art mass spectrometer, the maXis, capable of keeping pace with the current demands of high-throughput analysis without sacrificing accuracy, sensitivity or resolution. In this study the maXis was capable of delivering:
For research use only. Not for use in diagnostic procedures.
Bruker Daltonik GmbH
Fahrenheitstr. 4, 28359 Bremen, Germany
tel. +49 421 2205 0 fax +49 421 2205 104
E-mail: sales@bdal.de
Website: www.bdal.com
A Guide To Finding the Ideal Syringe and Needle
January 20th 2025Hamilton has produced a series of reference guides to assist science professionals in finding the best-suited products and configurations for their applications. The Syringe and Needle Reference Guide provides detailed information on Hamilton Company’s full portfolio of syringes and needles. Everything from cleaning and preventative maintenance to individual part numbers are available for review. It also includes selection charts to help you choose between syringe terminations like cemented needles and luer tips.
Oasis or Sand Dune? Isolation of Psychedelic Compounds
January 20th 2025Magic mushrooms, once taboo, have recently experienced a renaissance. This new awakening is partially due to new findings that indicate the effects of psilocybin, and its dephosphorylated cousin psilocin may produce long lasting results for patients who might be struggling with anxiety, depression, alcohol and drug abuse, and post-traumatic stress disorder. Hamilton Company has developed a methodology for the isolation and identification of 5 common psychedelic compounds used in the potential treatment of disease. The PRP-1 HPLC column resin remains stable in the harsh alkaline conditions ideal for better separations.
GPCRs – The Biological Traffic Modulator: Chromatographic Analysis of Peptides in the GI Tract
January 20th 2025The G protein-coupled receptors (GPCR) are found throughout the entire body and have shown significance in the development of new therapeutic treatments. Isolation of seven classic GRPC peptides initiating in the GI tract highlights the benefits of using the polymer-based PRP-3, a reversed-phase resin. The covalent bonds found in the PRP-3 exhibit advantageous interactions between the biological π bonds found in the peptides and the available aromatic benzyl rings of the resin.